Ataxia Telangiectasia Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight

DelveInsight's "Ataxia Telangiectasia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Ataxia Telangiectasia, historical and forecasted epidemiology as well as the Ataxia Telangiectasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ataxia Telangiectasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ataxia Telangiectasia Market Forecast
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Ataxia Telangiectasia Market Report:
• The Ataxia Telangiectasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2025, Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on leveraging a patient's own biology to treat rare diseases, has announced the online publication of safety data in Frontiers in Neurology for patients with Ataxia-Telangiectasia (A-T) treated with EryDex for at least 24 months. A-T is a rare pediatric disease with no approved treatments and significant unmet medical need. This post-hoc analysis, based on data from a Phase 3 ATTeST clinical trial and an open-label extension study, demonstrates the potential of EryDex, which delivers dexamethasone sodium phosphate encapsulated in a patient's own red blood cells, to provide therapeutic benefits without the debilitating toxicities associated with standard corticosteroid treatments.
• In November 2024, Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on harnessing a patient's own biology to treat rare diseases, has announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR). The posters highlight data from its previous Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial, which evaluated the company's lead asset, EryDex (intra-erythrocyte dexamethasone sodium phosphate), for the treatment of Ataxia-Telangiectasia.
• In June 2024, Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotech company focused on innovative drug delivery technology using a patient's own biology for rare disease treatments, announced the dosing of the first patient in its Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T) clinical trial. This pivotal study, evaluating the neurological effects of EryDex in patients with Ataxia-Telangiectasia (A-T), is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food & Drug Administration (FDA).
• As per Giulietta et al.'s research in 2021, around 1% of the U.S. population carries a mutation in the Ataxia-Telangiectasia mutated kinase (ATM) gene.
• Approximately 1% of the U.S. population carries a mutation in the ATM gene, affecting both males and females equally. Ataxia Telangiectasia ranks as the second most prevalent autosomal recessive ataxia in children, following Friedreich's ataxia. Notably, it stands as the most frequent genetic ataxia with an onset during the initial decade of life.
• GTX-102, IB1001, and other upcoming Ataxia Telangiectasia treatments are demonstrating favorable topline outcomes in their clinical trials. Positioned in the middle phase of clinical development, these promising therapies are poised for a potential launch, contributing to the strengthening of the treatment pipeline.
• Key Ataxia Telangiectasia Companies: Quince Therapeutics S.p.A., IntraBio Inc, EMD Serono R&D, Artios Pharma Ltd, AstraZeneca, Actuate Therapeutics Inc., Acasti Pharma Inc., IntraBio Inc., and others
• Key Ataxia Telangiectasia Therapies: Dexamethasone sodium phosphate, IB1001, Tuvusertib (M1774), ART0380, Ceralasertib, Doxorubicin, GTX-102, and others
• The Ataxia Telangiectasia epidemiology based on gender analyzed that males and females are affected in equal numbers
• The Ataxia Telangiectasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ataxia Telangiectasia pipeline products will significantly revolutionize the Ataxia Telangiectasia market dynamics.

Ataxia Telangiectasia Overview
Ataxia Telangiectasia (AT) is a rare, inherited neurodegenerative disorder that affects multiple systems in the body, particularly the nervous and immune systems. It is characterized by progressive difficulty with movement coordination (ataxia), dilated blood vessels (telangiectasias) in the eyes and skin, and a high susceptibility to infections and cancers, especially leukemia and lymphoma.

Get a Free sample for the Ataxia Telangiectasia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ataxia Telangiectasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ataxia Telangiectasia Epidemiology Segmentation:
The Ataxia Telangiectasia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Ataxia Telangiectasia
• Prevalent Cases of Ataxia Telangiectasia by severity
• Gender-specific Prevalence of Ataxia Telangiectasia
• Diagnosed Cases of Episodic and Chronic Ataxia Telangiectasia

Download the report to understand which factors are driving Ataxia Telangiectasia epidemiology trends @ Ataxia Telangiectasia Epidemiology Forecast
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ataxia Telangiectasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ataxia Telangiectasia market or expected to get launched during the study period. The analysis covers Ataxia Telangiectasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ataxia Telangiectasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ataxia Telangiectasia Therapies and Key Companies
• Dexamethasone sodium phosphate: Quince Therapeutics S.p.A.
• IB1001: IntraBio Inc
• Tuvusertib (M1774): EMD Serono R&D
• ART0380: Artios Pharma Ltd
• Ceralasertib: AstraZeneca
• Doxorubicin: Actuate Therapeutics Inc
• GTX-102: Acasti Pharma Inc.
• IB1001-203: IntraBio Inc.

Discover more about therapies set to grab major Ataxia Telangiectasia market share @ Ataxia Telangiectasia Treatment Landscape
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Ataxia Telangiectasia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ataxia Telangiectasia Companies: Quince Therapeutics S.p.A., IntraBio Inc, EMD Serono R&D, Artios Pharma Ltd, AstraZeneca, Actuate Therapeutics Inc., Acasti Pharma Inc., IntraBio Inc., and others
• Key Ataxia Telangiectasia Therapies: Dexamethasone sodium phosphate, IB1001, Tuvusertib (M1774), ART0380, Ceralasertib, Doxorubicin, GTX-102, and others
• Ataxia Telangiectasia Therapeutic Assessment: Ataxia Telangiectasia current marketed and Ataxia Telangiectasia emerging therapies
• Ataxia Telangiectasia Market Dynamics: Ataxia Telangiectasia market drivers and Ataxia Telangiectasia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ataxia Telangiectasia Unmet Needs, KOL's views, Analyst's views, Ataxia Telangiectasia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.